Barnett J B
Int Arch Allergy Appl Immunol. 1983;72(3):227-33. doi: 10.1159/000234872.
The results reported here provide information on the effects of 13-cis retinoic acid (13-cRA) on the IgG and IgM responses in BALB/c mice. For these studies, a suboptimum immunizing concentration of ovalbumin (1 microgram) was used. BALB/c mice were given either 13-cRA or control beadlets (gel) as either 1 dose (at day -1) or 4 doses (at week -3, -2, -1, and day -1) prior to primary immunization, or 4 doses prior to, and 4 doses after, primary immunization (week -3, -2, -1, day -1, week 1, 2, 3, and day 27). The results consistently showed no primary antibody response and excellent secondary antibody levels in all 13-cRA-treated groups. Attempts to determine whether the 13-cRA affected the afferent or efferent phase of antibody induction by varying the time of the administration of a single 13-cRA dose, relative to immunization, showed no difference in the results in animals treated on day -2 to day 3.
此处报告的结果提供了关于13-顺式维甲酸（13-cRA）对BALB/c小鼠IgG和IgM反应影响的信息。在这些研究中，使用了亚最佳免疫浓度的卵清蛋白（1微克）。在初次免疫前，给BALB/c小鼠注射13-cRA或对照微丸（凝胶），剂量为1次（在第-1天）或4次（在第-3周、-2周、-1周和第-1天），或者在初次免疫前和初次免疫后各注射4次（第-3周、-2周、-1周、第-1天、第1周、第2周、第3周和第27天）。结果始终表明，在所有接受13-cRA治疗的组中，没有初次抗体反应，但二次抗体水平良好。通过改变相对于免疫时间的单次13-cRA剂量给药时间，试图确定13-cRA是否影响抗体诱导的传入或传出阶段，结果显示在第-2天至第3天接受治疗的动物中，结果没有差异。
